Personalized medicine in Alzheimer's disease and depression

Contemporary Clinical Trials

Volumn 36, Issue 2, 2013, Pages 616-623

  Souslova, Tatiana ^a,b   Marple, Teresa C ^a   Spiekerman, A Michael ^a   Mohammad, Amin A ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b ACM Medical Laboratory Rochester   (United States)

Author keywords

Alzheimer's disease; Depression; Epigenetics; Personalized medicine

Indexed keywords

ALPHA 1 ANTITRYPSIN; AMYLOID PRECURSOR PROTEIN; CITALOPRAM; DONEPEZIL; FLUORINE 18; HYDROCORTISONE; MEMANTINE; MYELOPEROXIDASE; NEUROTROPHIC FACTOR; PROLACTIN; PROTEIN S 100; RECEPTOR; RESISTIN; TAU PROTEIN; THREONINE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; AUTOPSY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL STUDY; DIAGNOSTIC TEST; DNA POLYMORPHISM; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LABORATORY DEVICE; MAJOR DEPRESSION; MILD COGNITIVE IMPAIRMENT; NEUROFIBRILLARY TANGLE; NONHUMAN; PERSONALIZED MEDICINE; PHARMACOGENETICS; POSITRON EMISSION TOMOGRAPHY; REVIEW; SENSITIVITY AND SPECIFICITY;

5-HTT; 5-HTTLPR; 5-HYDROXYTRYPTAMINE TRANSPORTER GENE; AD; ADNI; ADRDA; ALZHEIMER'S DISEASE; ALZHEIMER'S DISEASE AND RELATED DISORDERS ASSOCIATION; ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE; AΒ40; AΒ42; BETA-AMYLOID, AMINO ACIDS 1-40; BETA-AMYLOID, AMINO ACIDS 1-42; CAMP RESPONSE ELEMENT-BINDING PROTEIN; CEREBROSPINAL FLUID; COEFFICIENT OF VARIATION; COMPUTED TOMOGRAPHY; CREB; CSF; CT; CV; CYP2C19; CYP2D6; CYP450; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DEOXYRIBONUCLEIC ACID; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS-FIFTH EDITION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS-FOURTH EDITION-TEXT REVISION; DNA; DSM; DSM-IV-TR; DSM-V; ELISA; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIGENETICS; FDA; FK506-BINDING PROTEIN; FKBP5; FOOD AND DRUG ADMINISTRATION; GLUTAMATE RECEPTOR, IONOTROPIC, AMPA; GLUTAMATE RECEPTOR, IONOTROPIC, KAINATE; GRIA; GRIK; HPA; HYPOTHALAMIC-PITUITARY-ADRENAL; IL28RA; INTERLEUKIN 28 RECEPTOR, ALPHA (INTERFERON, LAMBDA RECEPTOR); KCNK2; MAGNETIC RESONANCE IMAGING; MAJOR DEPRESSIVE DISORDER SCORE; MDDSCORE; METHYLTHIONINIUM CHLORIDE; MRI; MTC; NATIONAL INSTITUTE OF NEUROLOGICAL AND COMMUNICATIVE DISORDERS AND STROKE; NINCDS; P-TAU181P; PAPILIN, PROTEOGLYCAN-LIKE SULFATED GLYCOPROTEIN; PAPLN; PERSONALIZED MEDICINE; PET; POSITRON EMISSION TOMOGRAPHY; POTASSIUM CHANNEL, SUBFAMILY K, MEMBER 2; QC; QUALITY CONTROL; RDOC; RESEARCH DOMAIN CRITERIA; RIBONUCLEIC ACID; RNA; SELECTIVE SEROTONIN REUPTAKE INHIBITOR; SEQUENCED TREATMENT ALTERNATIVES TO RELIEVE DEPRESSION; SEROTONIN-TRANSPORTER-GENE-LINKED POLYMORPHIC REGION; SSRI; STAR*D; T-TAU; TAU PHOSPHORYLATED AT THREONINE 181; TOTAL TAU; VARIABLE NUCLEOTIDE TERMINAL REPEAT; VNTR; WHO; WORLD HEALTH ORGANIZATION;

ALZHEIMER DISEASE; ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSIVE DISORDER, MAJOR; HUMANS; INDIVIDUALIZED MEDICINE; NOOTROPIC AGENTS;

EID: 84888132481     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2013.06.012     Document Type: Review

References (82)

1. Higgins E.S., George M.S. Neuroscience of clinical psychiatry: the pathophysiology of behavior and mental illness 2007, Lippincott, Philadelphia.
2. Bloom D.E., Cafiero E.T., Jané-Llopis E., Abrahams-Gessel S., Bloom L.R., Fathima S., Feigl A.B., et al. The global economic burden of non-communicable diseases 2011, World Economic Forum, Geneva.
3. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, [Text Revision (DSM-IV-TR®)]. 4th ed.
4. Kraemer H.C., Kupfer D.J., Clarke D.E., Narrow W.E., Regier D.A. DSM-5: how reliable is reliable enough?. Am J Psychiatry 2012, 169(1):13-15.
5. International Classification of Diseases-10 Chapter 5. Classification of mental and behavioural disorders. Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization.
6. Willard H.W. Organization, variation and expression of the human genome as a foundation of genomic and personalized medicine. Genomic and personalized medicine 2009, 4-21. Academic Press, London UK. H.W. Willard, G.S. Ginsburg (Eds.).
7. McMahon F.J., Insel T.R. Pharmacogenomics and personalized medicine in neuropsychiatry. Neuron 2012, 74(5):773-776.
8. Kapur S., Phillips A.G., Insel T.R. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it?. Mol Psychiatry 2012, 17(12):1174-1179.
9. National Institute of Mental Health website:, [last accessed 6/11/2013]. http://www.nimh.nih.gov/research-priorities/rdoc/nimh-research-domain-criteria-rdoc.shtml.
10. Brookmeyer R., Evans D.A., Hebert L., Langa K.M., Heeringa S.G., Plassman B.L., et al. National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimers Dement Jan 2011, 7(1):61-73.
11. Alzheimer's Association 2012 Alzheimer's disease facts and figures. Alzheimers Dement 2012, 8(2):131-168.
12. Povova J., Ambroz P., Bar M., Pavukova V., Sery O., Tomaskova H., et al. Epidemiological of and risk factors for Alzheimer's disease: a review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Jun 2012, 156(2):108-114. [Review].
13. Cruts M., Theuns J., Van Broeckhoven C. Locus-specific mutation databases for neurodegenerative brain diseases. Hum Mutat 2012, 33:1340-1344.
14. Roses A.D. Apolipoprotein E affects the rate of Alzheimer disease expression: beta-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. J Neuropathol Exp Neurol 1994, 53(5):429-437. [PubMed: 8083686].
15. Liu C.C., Kanekiyo T., Xu H., Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol Feb 2013, 9(2):106-118. [PMID: 23296339].
16. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol Aug 2007, 6(8):734-746. [Review].
17. McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7(3):263-269.
18. Jack C.R., Albert M.S., Knopman D.S., McKhann G.M., Sperling R.A., Carrillo M.C., et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement May 2011, 7(3):257-262.
19. Price J.L., Morris J.C. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol Mar 1999, 45(3):358-368.
20. Romano M., Buratti E. Florbetapir F 18 for brain imaging of β-amyloid plaques. Drugs Today (Barc) Mar 2013, 49(3):181-193.
21. Sinha S., Lieberburg I. Cellular mechanisms of beta-amyloid production and secretion. Proc Natl Acad Sci U S A Sep 28 1999, 96(20):11049-11053. [Review].
22. Chintamaneni M., Bhaskar M. Biomarkers in Alzheimer's disease: a review. ISRN, Pharmacology 2012, 984786. [(Mci)].
23. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Clark C.M., Aisen P.S., Petersen R.C., et al. Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimer's Disease Neuroimaging Initiative. Ann Neurol Apr 2009, 65(4):403-413.
24. Hyman B.T., Phelps C.H., Beach T.G., Bigio E.H., Cairns N.J., Carrillo M.C., et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012, 8(1):1-13.
25. Mattsson N., Andreasson U., Persson S., Arai H., Batish S.D., Bernardini S., et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 2011, 7(4):386-395.e6.
26. Mattsson N., Andreasson U., Carrillo M.C., Persson S., Shaw L.M., Zegers I., et al. Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers. Biomark Med 2012, 6(4):401-407.
27. Fagan A.M., Perrin R.J. Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med 2012, 6(4):455-476.
28. Perneczky R., Guo L.H., Kagerbauer S.M., Werle L., Kurz A., Martin J., et al. Soluble amyloid precursor protein β as blood-based biomarker of Alzheimer's disease. Transl Psychiatry Feb 19 2013, 3:e227.
29. Bazenet C., Lovestone S. Plasma biomarkers for Alzheimer's disease: much needed but tough to find. Biomark Med 2012, 6(4):441-454.
30. Rosén C., Hansson O., Blennow K., Zetterberg H. Fluid biomarkers in Alzheimer's disease - current concepts. Mol Neurodegener Jun 21 2013, 8(20).
31. Reiman E.M., Quiroz Y.T., Fleisher A.S., Chen K., Velez-Pardo C., Jimenez-Del-Rio M., et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol Dec 2012, 11(12):1048-1056.
32. Doecke J.D., Laws S.M., Faux N.G., Wilson W., Burnham S.C., Lam C.P., et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Alzheimer's Disease Neuroimaging Initiative; Australian Imaging Biomarker and Lifestyle Research Group. Arch Neurol Oct 2012, 69(10):1318-1325.
33. Salloway S., Correia S. Alzheimer disease: time to improve its diagnosis and treatment. Cleve Clin J Med 2009, 76:49-58.
34. Tayeb H.O., Yang H.D., Price B.H., Tarazi F.I. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. Pharmacol Ther 2012, 134(1):8-25.
35. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400(6740):173-177.
36. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology Jul 8 2003, 61(1):46-54.
37. Moreth J., Mavoungou C., Schindowski K. Passive anti-amyloid immunotherapy in Alzheimer's disease: what are the most promising targets?. Immunol Ageing May 11 2013, 10(1):18.
38. Wadman M. US government sets out Alzheimer's plan. Nature May 22 2012, 485(7399):426-427.
39. Galimberti D., Scarpini E. Disease-modifying treatments for Alzheimer's disease. Ther Adv Neurol Disord Jul 2011, 4(4):203-216.
40. Kozauer N., Katz R. Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med Mar 28 2013, 368(13):1169-1171.
41. [last accessed 6/12/2013]. http://www.alz.org/documents_custom/final_adni_genome_sequencing_news_release.pdf.
42. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron Mar 28 2002, 34(1):13-25. [Review].
43. Palazidou E. The neurobiology of depression. Br Med Bull 2012, 101:127-145. [Review].
44. WHO "Mental health atlas". Mental disorders. Depression fact sheet 2005, World Health Organization, Geneva.
45. Carroll B.J., Curtis G.C., Mendels J. Neuroendocrine regulation in depression. II. Discrimination of depressed from nondepressed patients. Arch Gen Psychiatry 1976, 33(9):1051-1058.
46. Carroll B.J., Feinberg M., Greden J.F., Haskett R.F., James N.M., Steiner M., et al. Diagnosis of endogenous depression. Comparison of clinical, research and neuroendocrine criteria. J Affect Disord 1980, 2(3):177-194.
47. Carroll B.J., Feinberg M., Greden J.F., Tarika J., Albala A.A., Haskett R.F., et al. A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch Gen Psychiatry 1981, 38(1):15-22.
48. American Psychiatric Association The dexamethasone suppression test: an overview of its current status in psychiatry. Am J Psychiatry 1987, 144:1253-1262.
49. Papakostas G.I., Shelton R.C., Kinrys G., Henry M.E., Bakow B.R., Lipkin S.H., et al. Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study. Mol Psychiatry December 13 2011, 1-8.
50. Diagnostics, Ridge. "MDDScore™ Product Brief": 110. "Improving the diagnosis of major depressive disorder: a new multi-analyte biomarker panel".
51. Kroenke K., Spitzer R.L., Williams J.B. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med Sep 2001, 16(9):606-613.
52. Gumnick J.F., Nemeroff C.B. Problems with currently available antidepressants. J Clin Psychiatry 2000, 51-4:5-15.
53. Peretti S., Judge R., Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000, 403:17-25. [Review].
54. Thomas K.L., Ellingrod V.L. Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions. Pharmacotherapy Jul 29 2009, 7:822-831. [Review].
55. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry Jan 2006, 163(1):28-40.
56. Hu X.-Z., Rush A.J., Charney D., Wilson A.F., Sorant A.J., Papanicolaou G.J., et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry 2007, 64(7):783-792.
57. Mrazek D.A., Rush A.J., Biernacka J.M., O'Kane D.J., Cunningham J.M., Wieben E.D., et al. SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet Apr 5 2009, 150B(3):341-351.
58. Lesch K.P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science Nov 29 1996, 274(5292):1527-1531.
59. Lovejoy E.A., Scott A.C., Fiskerstrand C.E., Bubb V.J., Quinn J.P. The serotonin transporter intronic VNTR enhancer correlated with a predisposition to affective disorders has distinct regulatory elements within the domain based on the primary DNA sequence of the repeat unit. Eur J Neurosci Jan 2003, 17(2):417-420.
60. Porcelli S., Fabbri C., Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol Apr 2012, 22(4):239-258. [Review].
61. Poland R.E., Lesser I.M., Wan Y.J., Gertsik L., Yao J., Raffel L.J., et al. Response to citalopram is not associated with SLC6A4 genotype in African-Americans and Caucasians with major depression. Life Sci May 30 2013, 92(20-21):967-970.
62. Paddock S., Laje G., Charney D., Rush A.J., Wilson A.F., Sorant A.J., et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry Aug 2007, 164(8):1181-1188.
63. Lekman M., Laje G., Charney D., Rush A.J., Wilson A.F., Sorant A.J., et al. The FKBP5-gene in depression and treatment response-an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Cohort Biol Psychiatry Jun 15 2008, 63(12):1103-1110.
64. Perlis R.H., Moorjani P., Fagerness J., Purcell S., Trivedi M.H., Fava M., et al. Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study. Neuropsychopharmacology Nov 2008, 33(12):2810-2819.
65. Laje G., Perlis R.H., Rush A.J., McMahon F.J. Pharmacogenetics studies in STAR*D: strengths, limitations, and results. Psychiatr Serv Nov 2009, 60(11):1446-1457.
66. Porcelli S., Drago A., Fabbri C., Gibiino S., Calati R., Serretti A. Pharmacogenetics of antidepressant response. J Psychiatry Neurosci 2011, 36(2):87-113.
67. Spina E., Santoro V., D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther Jul 2008, 30(7):1206-1227. [Review].
68. Mrazek D.A. Psychiatric pharmacogenomic testing in clinical practice. Dialogues Clin Neurosci 2010, 12(1):69-76. [Review].
69. de Leon J., Susce M.T., Johnson M., Hardin M., Maw L., Shao A., et al. DNA microarray technology in the clinical environment: the AmpliChip CYP450 Test for CYP2D6 and CYP2C19 genotyping. CNS Spectr 2009, 14(1):19-34.
70. de Leon J. Pharmacogenomics: the promise of personalized medicine for CNS disorders. Neuropsychopharmacology 2009, 34(1):159-172.
71. Mazzio E.A., Karam F.A.S. Basic concepts of epigenetics: impact of environmental signals on gene expression. Epigenetics 2012, 7(2):119-130.
72. Dauncey M.J. Genomic and epigenomic insights into nutrition and brain disorders. Nutrients Mar 15 2013, 5(3):887-914.
73. Szyf M. The early life social environment and DNA methylation: DNA methylation mediating the long-term impact of social environments early in life. Epigenetics Aug 2011, 6(8):971-978. [Review].
74. Masri S., Sassone-Corsi P. The circadian clock: a framework linking metabolism, epigenetics and neuronal function. Nat Rev Neurosci Jan 2013, 14(1):69-75.
75. Hodes G.E. Sex, stress, and epigenetics: regulation of behavior in animal models of mood disorders. Biol Sex Differ Jan 21 2013, 4(1):1.
76. Lim J.P., Brunet A. Bridging the transgenerational gap with epigenetic memory. Trends Genet Mar 2013, 29(3):176-186.
77. Weaver I.C., Cervoni N., Champagne F.A., D'Alessio A.C., Sharma S., Seckl J.r, et al. Epigenetic programming by maternal behavior. Nat Neurosci Aug 2004, 7(8):847-854.
78. McGowan P.O., Sasaki A., D'Alessio A.C., Dymov S., Labonté B., Szyf M., et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci Mar 2009, 12(3):342-348.
79. Baer-Dubowska W., Majchrzak-Celińska A., Cichocki M. Pharmacoepigenetics: a new approach to predicting individual drug responses and targeting new drugs. Pharmacol Rep 2011, 63(2):293-304. [Review].
80. Gomez A., Ingelman-Sundberg M. Pharmacoepigenetics: its role in interindividual differences in drug response. Clin Pharmacol Ther Apr 2009, 85(4):426-430. [Review].
81. 18F-FAHA. Neuroimage Jan 1 2013, 64:630-639.
82. Hall-Flavin D.K., Winner J.G., Allen J.D., Jordan J.J., Nesheim R.S., Snyder K.A., et al. Using a pharmacogenomic algorithm to guide the treatment of depression. Transl Psychiatry Oct 16 2012, 2:e172.